Room+for+improvement


 * 1) [[file:YouEtal2009.pdf]]:
 * Lower genotyping cost, improve effectiveness of INR control of the genotype-guided dosing algorithm, apply the algorithm in practice sites with high out-of-range INRs.
 * Factors that affect the outcome estimation that are not evaluated in the model: turnaround time for genetic testing, racial differences in frequencies of allelic variants, and education and training of AC staff.
 * Up to date, there is no published randomized clinical trials on genotype-guided dosing with sufficient power to measure the change in adverse event rates as the primary outcomes. Surrogate outcomes such as percentage of out-of-range INRs and percentage of patient-time spent within the therapeutic range were reported as the primary end points instead.